anti-EGFR capture mitigates EMT- and chemoresistance-associated heterogeneity in a resistance-profiling CTC platform

Thege, Fredrik I.; Gruber, Conor; Cardle, Ian I.; Cong, Sophie H.; Lannin, Timothy B.; Kirby, Brian J.

doi:10.1016/j.ab.2019.02.003

Cited by 12 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to occupy and colonize in distant tissues, cancer cells use EMT mechanism to promote their migratory ability [ 57 , 58 , 59 , 60 ]. It has been noted that EMT mechanism not only ensures invasion of cancer cells, but also is involved in reducing sensitivity of cancer cells into apoptosis and stimulation of chemoresistance [ 61 , 62 ]. EMT is not a binary state procedure and has a dynamic spectrum in which cells can have both epithelial and mesenchymal features [ 63 , 64 , 65 , 66 , 67 , 68 ].…”

Section: Emt Mechanismmentioning

confidence: 99%

Role of microRNA/Epithelial-to-Mesenchymal Transition Axis in the Metastasis of Bladder Cancer

et al. 2020

View full text Add to dashboard Cite

Bladder cancer (BC) is the 11th most common diagnosed cancer, and a number of factors including environmental and genetic ones participate in BC development. Metastasis of BC cells into neighboring and distant tissues significantly reduces overall survival of patients with this life-threatening disorder. Recently, studies have focused on revealing molecular pathways involved in metastasis of BC cells, and in this review, we focus on microRNAs (miRNAs) and their regulatory effect on epithelial-to-mesenchymal transition (EMT) mechanisms that can regulate metastasis. EMT is a vital process for migration of BC cells, and inhibition of this mechanism restricts invasion of BC cells. MiRNAs are endogenous non-coding RNAs with 19–24 nucleotides capable of regulating different cellular events, and EMT is one of them. In BC cells, miRNAs are able to both induce and/or inhibit EMT. For regulation of EMT, miRNAs affect different molecular pathways such as transforming growth factor-beta (TGF-β), Snail, Slug, ZEB1/2, CD44, NSBP1, which are, discussed in detail this review. Besides, miRNA/EMT axis can also be regulated by upstream mediators such as lncRNAs, circRNAs and targeted by diverse anti-tumor agents. These topics are also discussed here to reveal diverse molecular pathways involved in migration of BC cells and strategies to target them to develop effective therapeutics.

show abstract

Section: Emt Mechanismmentioning

confidence: 99%

Role of microRNA/Epithelial-to-Mesenchymal Transition Axis in the Metastasis of Bladder Cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Unfortunately, the expression of EpCAM and other surface markers on CTCs is inevitably heterogeneous in real samples. [22,23] For instance, those CTCs undergoing epithelial to mesenchymal transition (EMT) during tumor progression, would exhibit downregulated EpCAM expression. In this context, homo-ligand-based isolation, such as FDA-cleared CellSearch, is hampered by low efficacy when it comes to post-EMT CTCs.…”

Section: Introductionmentioning

confidence: 99%

Bioinspired DNA Nanointerface with Anisotropic Aptamers for Accurate Capture of Circulating Tumor Cells

et al. 2020

View full text Add to dashboard Cite

The capture and analysis of circulating tumor cells (CTCs) have provided a non-invasive entry for cancer diagnosis and disease monitoring. Despite recent development in affinity-based CTCs isolation, it remains challenging to achieve efficient capture toward CTCs with dynamic surface expression. Enlightened by the synergistic effect insideimmune synapses, the development of a nanointerface engineered with topology-defined anisotropic aptamers programmed by DNA scaffold (DNA nanosynapse), for accurate CTCs isolation, is herein reported. As compared to isotropic aptamers, the DNA nanosynapse exhibits enhanced anchoring on the cell membrane with both high and low epithelial cell adhesion molecule (EpCAM) expression. This nanointerface enables accurate capture toward CTCs of heterogeneous EpCAM, without dramatically proportional change inside the mixture of diverse phenotypes. By applying this nanoplatform, CTCs detection as well as downstream analysis for measuring disease status can be achieved in clinical samples from breast cancer patients.

show abstract

“…An in vitro model of EMT was developed to show that EMT-induction decreased EpCAM expression and as a result lower sensitivity of anti-EpCAM based recovery of cells. The researchers suggested that for CTC capture, targeting cells with EGFR antigens rather than EpCAM may be more robust, specifically in light of EMT, providing valuable insight for potential affinity-based separation methods …”

Section: Cell Separation Methodsmentioning

confidence: 99%

“…The researchers suggested that for CTC capture, targeting cells with EGFR antigens rather than EpCAM may be more robust, specifically in light of EMT, providing valuable insight for potential affinity-based separation methods. 34 CellSearch utilizes anti-EpCAM-functionalized magnetic beads to isolate CTCs from blood. A recently developed microfluidic device utilized a similar magnetic nanoparticlebased approach.…”

Section: ■ Cell Separation Methodsmentioning

confidence: 99%

Cell Separations and Sorting

2019

View full text Add to dashboard Cite

The development of new methods and technologies for cell separation, sorting, selection, isolation, or enrichment (many times the aforementioned terms are used interchangeably) are becoming more imperative due in part to the wealth of research aimed at addressing issues for the analysis of liquid biopsy targets, such as rare cells, to realize the concept of "precision medicine". Precision medicine is defined as "treatments targeted to the needs of individual patients on the basis of genetic, biomarker, phenotypic, or psychosocial characteristics that distinguish a patient from others with similar clinical presentations." 1 Before full implementation of precision medicine in a hospital or clinical setting, technological discoveries must be realized to assist in the analysis of disease-associated cells enriched from complex samples.Liquid biopsy markers and the cargo that they carry have been shown to be an attractive source of information that can be used to facilitate precise decisions for disease management. These biomarkers include, but are not limited to, rare cells such as circulating tumor cells (CTCs) or cancer stem cells (CSCs), immune cells (i.e., CD8+ T-cells), bacterial and viral cells, cell-free molecules such as cell free DNA (cfDNA), and extracellular vesicles (EVs). Liquid biopsies are attractive because of the minimally invasive nature of the sampling method (i.e., collection of peripheral blood, urine, saliva) to secure relevant biomarkers. These biomarkers can enable precision medicine decisions on managing a variety of diseases, including oncology and nononcology-related diseases. 2,3 Liquid biopsies *

show abstract

anti-EGFR capture mitigates EMT- and chemoresistance-associated heterogeneity in a resistance-profiling CTC platform

Cited by 12 publications

References 40 publications

Role of microRNA/Epithelial-to-Mesenchymal Transition Axis in the Metastasis of Bladder Cancer

Role of microRNA/Epithelial-to-Mesenchymal Transition Axis in the Metastasis of Bladder Cancer

Bioinspired DNA Nanointerface with Anisotropic Aptamers for Accurate Capture of Circulating Tumor Cells

Cell Separations and Sorting

Contact Info

Product

Resources

About